STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRMD
  4. [Form 4] MARIMED INC. Insider Trading Activity

MariMed (MRMD) CEO Jon Levine details RSU vesting and tax share withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported insider equity activity dated 12/15/2025. On that date, 89,859 restricted stock units vested and converted one-for-one into shares of common stock at a stated price of $0, increasing his direct holdings.

To satisfy related tax withholding obligations, 26,374 shares of common stock were withheld by MariMed at $0.1071 per share. Following these entries, Levine directly holds 21,136,200 MariMed common shares and has indirect beneficial ownership of 6,684,640 shares held by the Jon Levine Family Trust for the benefit of his spouse and children, which he formally disclaims for Section 16 purposes.

Positive

  • None.

Negative

  • None.
Insider Levine Jon R
Role President and CEO
Type Security Shares Price Value
Exercise Restricted Stock Units (RSU) 89,859 $0.00 --
Exercise Common stock 89,859 $0.00 --
Tax Withholding Common stock 26,374 $0.1071 $3K
holding Common stock -- -- --
Holdings After Transaction: Restricted Stock Units (RSU) — 0 shares (Direct); Common stock — 21,162,574 shares (Direct); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)
Footnotes (1)
  1. RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These RSUs were granted on May 9, 2025; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R
(Last) (First) (Middle)
C/O MARIMED INC.
10 OCEANA WAY
(Street)
NORWOOD, MA 02062
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 12/15/2025 M 89,859 A $0(1) 21,162,574 D
Common stock 12/15/2025 F 26,374(2) D $0.1071 21,136,200 D
Common stock 6,684,640 I By the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (RSU) (1) 12/15/2025 M 89,859 (4) (4) Common Stock, par value $.001 per share 89,859 $0 0 D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on May 9, 2025; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did MariMed (MRMD) report for Jon R. Levine?

The filing shows that Jon R. Levine had 89,859 restricted stock units (RSUs) vest and convert into MariMed common stock on 12/15/2025, with a portion of the resulting shares withheld to cover tax obligations.

How many MariMed (MRMD) shares did Jon R. Levine receive from RSU vesting?

On 12/15/2025, 89,859 RSUs held by Jon R. Levine vested and converted one-for-one into 89,859 shares of MariMed common stock at a stated price of $0.

How many shares were withheld to pay taxes in this MariMed (MRMD) transaction?

The report states that 26,374 shares of MariMed common stock were withheld by the issuer to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.1071 per share.

What is Jon R. Levines direct share ownership in MariMed (MRMD) after the transaction?

After the RSU vesting and tax share withholding entries, Jon R. Levine is shown as directly owning 21,136,200 shares of MariMed common stock.

What indirect MariMed (MRMD) holdings are reported for Jon R. Levine?

The filing reports that 6,684,640 MariMed shares are held indirectly through the Jon Levine Family Trust for the benefit of his spouse and children. Levine disclaims beneficial ownership of these securities for Section 16 and other purposes.

What roles does Jon R. Levine hold at MariMed (MRMD)?

Jon R. Levine is identified as a director, a 10% owner, and an officer of MariMed Inc., serving as President and CEO.